Efficacy of paroxetine on longitudinal ADL and QOL in post-stroke depression

点击翻译按钮获取中文摘要

We administered paroxetine, one of the selective serotonin reuptake inhibitor (SSRI), or nicergoline as a control to patients with post-stroke depression (PSD) for eight weeks and evaluated the severity of depression, disabilities of stroke and QOL for eight months. The severity of depression was improved at the group which administered paroxetine during a medicine dosage period in comparison with the control group, but did not recognize a difference in ability of gait and ADL at the time of the medicine dosage end. However, it was the tendency that the hospitalization came to shorten in the group which administered paroxetine. The dosage of the SSRI for PSD did not affect longitudinal ADL and QOL. But it improves depression early to diagnose as PSD and administer SSRI, and it may shorten hospitalization.